Advanced or Metastatic Solid Tumors | Norton Healthcare

Indication: Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation

Sub-indication: Advanced or Metastatic Solid Tumors

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: InventisBio US

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.